SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy
Phase 1
Active, not recruiting
- Conditions
- Partial Response of Multiple Myeloma or Plasma Cell LeukemiaPlasma Cell Myeloma
- Interventions
- Other: Laboratory Biomarker Analysis
- First Posted Date
- 2015-01-08
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 18
- Registration Number
- NCT02334865
- Locations
- ๐บ๐ธ
Roswell Park Cancer Institute, Buffalo, New York, United States
๐บ๐ธUniversity of Rochester Medical Center, Rochester, New York, United States
Regorafenib in Reducing Recurrence in Patients With Non-metastatic Rectal Cancer Who Have Completed Curative-Intent Treatment
Phase 2
Withdrawn
- Conditions
- Stage IIB Rectal CancerRectal AdenocarcinomaStage IIA Rectal CancerStage IIC Rectal CancerStage IIIA Rectal CancerStage IIIB Rectal Cancer
- Interventions
- Other: Laboratory Biomarker Analysis
- First Posted Date
- 2014-11-11
- Last Posted Date
- 2016-10-12
- Lead Sponsor
- Roswell Park Cancer Institute
- Registration Number
- NCT02287727
- Locations
- ๐บ๐ธ
Roswell Park Cancer Institute, Buffalo, New York, United States
๐บ๐ธUniversity of Rochester Medical Center - Wilmont Cancer Institute, Rocherster, New York, United States
๐บ๐ธOhio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer
Phase 1
Completed
- Conditions
- Stage IV Pancreatic CancerAdvanced Malignant Solid NeoplasmMetastatic Pancreatic AdenocarcinomaALK PositiveStage III Pancreatic Cancer
- Interventions
- Other: Laboratory Biomarker AnalysisOther: Pharmacological Study
- First Posted Date
- 2014-08-28
- Last Posted Date
- 2022-07-25
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 38
- Registration Number
- NCT02227940
- Locations
- ๐บ๐ธ
Roswell Park Cancer Institute, Buffalo, New York, United States
Vaccine Therapy Before Surgery in Treating Patients With Localized Kidney Cancer
Not Applicable
Terminated
- Conditions
- Stage II Renal Cell CancerRecurrent Renal Cell CarcinomaStage I Renal Cell Cancer
- Interventions
- Other: Laboratory Biomarker AnalysisProcedure: NephrectomyBiological: Renal Cell Carcinoma/CD40L RNA-Transfected Autologous Dendritic Cell Vaccine AGS-003
- First Posted Date
- 2014-06-23
- Last Posted Date
- 2020-07-07
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 5
- Registration Number
- NCT02170389
- Locations
- ๐บ๐ธ
Roswell Park Cancer Institute, Buffalo, New York, United States
DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission
Phase 1
Completed
- Conditions
- Fallopian Tube CarcinomaOvarian CarcinomaPrimary Peritoneal Carcinoma
- Interventions
- Biological: DEC-205/NY-ESO-1 Fusion Protein CDX-1401Other: Laboratory Biomarker AnalysisOther: Pharmacological Study
- First Posted Date
- 2014-06-18
- Last Posted Date
- 2023-02-24
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 40
- Registration Number
- NCT02166905
- Locations
- ๐บ๐ธ
Roswell Park Cancer Institute, Buffalo, New York, United States
Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Phase 2
Completed
- Conditions
- Metastatic Prostate CarcinomaHormone-Resistant Prostate CancerRecurrent Prostate CarcinomaStage IV Prostate Cancer
- Interventions
- First Posted Date
- 2014-06-10
- Last Posted Date
- 2023-04-27
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 2
- Registration Number
- NCT02159950
- Locations
- ๐บ๐ธ
Roswell Park Cancer Institute, Buffalo, New York, United States
Photodynamic Therapy With HPPH in Treating Patients With Squamous Cell Carcinoma of the Oral Cavity
Phase 2
Withdrawn
- Conditions
- Stage I Squamous Cell Carcinoma of the Lip and Oral CavityStage III Squamous Cell Carcinoma of the Lip and Oral CavityStage I Verrucous Carcinoma of the Oral CavityStage II Verrucous Carcinoma of the Oral CavityRecurrent Squamous Cell Carcinoma of the OropharynxRecurrent Verrucous Carcinoma of the Oral CavityStage II Squamous Cell Carcinoma of the Lip and Oral CavityStage III Verrucous Carcinoma of the Oral CavityStage IVA Verrucous Carcinoma of the Oral CavityStage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity
- Interventions
- First Posted Date
- 2014-04-22
- Last Posted Date
- 2016-04-21
- Lead Sponsor
- Roswell Park Cancer Institute
- Registration Number
- NCT02119728
- Locations
- ๐บ๐ธ
Roswell Park Cancer Institute, Buffalo, New York, United States
Narrative or Fact-Based Videos in Increasing Colorectal Cancer Screenings in African American Communities
Not Applicable
Completed
- Conditions
- Colorectal CancerHealthy, no Evidence of Disease
- Interventions
- Behavioral: behavioral intervention
- First Posted Date
- 2014-03-31
- Last Posted Date
- 2022-07-22
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 1310
- Registration Number
- NCT02100254
- Locations
- ๐บ๐ธ
Roswell Park Cancer Institute, Buffalo, New York, United States
๐บ๐ธMount Sinai School of Medicine, New York, New York, United States
Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
Not Applicable
Completed
- Conditions
- Localized Non-Resectable Adult Hepatocellular CarcinomaStage IIIB Hepatocellular CarcinomaAdvanced Adult Hepatocellular CarcinomaStage IVB Hepatocellular CarcinomaStage III Childhood Hepatocellular CarcinomaStage IIIA Hepatocellular CarcinomaStage IIIC Hepatocellular CarcinomaStage IV Childhood Hepatocellular CarcinomaStage IVA Hepatocellular Carcinoma
- Interventions
- Other: Laboratory Biomarker Analysis
- First Posted Date
- 2014-02-26
- Last Posted Date
- 2022-07-25
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 30
- Registration Number
- NCT02072486
- Locations
- ๐บ๐ธ
Roswell Park Cancer Institute, Buffalo, New York, United States
Interstitial Photodynamic Therapy in Treating Patients With Recurrent Head and Neck Cancer
Phase 2
Terminated
- Conditions
- Recurrent Lip and Oral Cavity Squamous Cell CarcinomaRecurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult PrimaryRecurrent Laryngeal Squamous Cell CarcinomaRecurrent Oropharyngeal Squamous Cell CarcinomaRecurrent Oral Cavity Verrucous CarcinomaRecurrent Laryngeal Verrucous CarcinomaTongue Carcinoma
- Interventions
- First Posted Date
- 2014-02-21
- Last Posted Date
- 2017-10-11
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 3
- Registration Number
- NCT02068157
- Locations
- ๐บ๐ธ
Roswell Park Cancer Institute, Buffalo, New York, United States